Better Therapeutics Inc
OTC:BTTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0001
0.0001
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Better Therapeutics Inc
Better Therapeutics, Inc. develops a software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2021-01-08. The firm creates treatments to reverse the progression of disease, improve quality of life, and inform clinical decisions. The company builds prescription digital therapeutics that deliver a new kind of behavioral therapy and creating feedback mechanisms using remotely-monitored and patient-generated data. Its clinical development pipeline includes BT-001, BT-002, BT-003, BT-004 and BT-005. The company is evaluating BT-001 in a pivotal study as a prescribed treatment used under physician supervision for people with uncontrolled type 2 diabetes. The firm develops Nutritional Cognitive Behavioral Therapy (Nutritional CBT), which is a novel form of behavioral therapy under development for the treatment of patients with type 2 diabetes and other cardiometabolic diseases.
Better Therapeutics, Inc. develops a software-based prescription digital therapeutics for treating diabetes, heart disease, and other cardiometabolic conditions. The company is headquartered in New York City, New York and currently employs 44 full-time employees. The company went IPO on 2021-01-08. The firm creates treatments to reverse the progression of disease, improve quality of life, and inform clinical decisions. The company builds prescription digital therapeutics that deliver a new kind of behavioral therapy and creating feedback mechanisms using remotely-monitored and patient-generated data. Its clinical development pipeline includes BT-001, BT-002, BT-003, BT-004 and BT-005. The company is evaluating BT-001 in a pivotal study as a prescribed treatment used under physician supervision for people with uncontrolled type 2 diabetes. The firm develops Nutritional Cognitive Behavioral Therapy (Nutritional CBT), which is a novel form of behavioral therapy under development for the treatment of patients with type 2 diabetes and other cardiometabolic diseases.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
